MedTrace Logo

Gadofosveset Trisodium for Heart Imaging Studies

NCT01853592 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-09-10

No results posted yet for this study

Summary

Background:

\- Magnetic resonance imaging (MRI) is type of imaging study that uses magnetic fields and radio waves to take pictures of the body. To help the images show up more clearly, a contrast agent is injected into a vein. Researchers are interested in finding contrast agents that can help show problems with the blood vessels around the heart. They want to test an agent called Gadofosveset Trisodium to see how it works in MRI scans.

Objectives:

\- To test the effectiveness of Gadofosveset Trisodium as a contrast agent in heart MRI scans.

Eligibility:

\- Healthy volunteers between 18 and 45 years of age.

Design:

* Participants will be screened with a physical exam and medical history. They will provide blood samples before the scanning sessions.
* Participants will have an MRI scan after the screening visit. They will have a dose of the contrast scan before the study.
* Participants will return for one additional MRI scan within 1 to 2 months of each scan. Different doses of the contrast agent will be used for each scan.
* An additional blood sample will be collected within 1 week of the second MRI scan.

Conditions

  • Obstructive Coronary Artery Disease
  • Coronary Arteriosclerosis
  • Coronary Artery Disease (CAD)

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • David A Bluemke, M.D. · National Institutes of Health Clinical Center (CC)

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-08
Primary Completion
2014-02-11
Completion
2016-12-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01853592 on ClinicalTrials.gov